Clinical Trial

TAG1 and PharmaLogic Announce Strategic Partnership to Advance Decentralized Lead-212 Generator Development

Collaboration accelerates TAG1's Pb-212 generator development and supports PharmaLogic's mission to scale radiopharmaceutical innovation. ST. LOUIS, June 24, 2025 /PRNewswire/…

6 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical…

6 months ago

Innovate GBM Rings the NASDAQ Closing Bell in Honor of Brain Tumor Patients and Community

Innovate GBM Community Innovate GBM’s Community Members gather at the NASDAQ Closing Bell Ceremony—united in a mission to bridge the…

6 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

FDA has indicated that an Advisory Committee meeting is not required at this timeIn-person late-cycle review meeting scheduled for mid-July…

6 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or…

6 months ago

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch…

6 months ago

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer

Enrollment is now underway across multiple clinical sites, in partnership with Syneos HealthVANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) --…

6 months ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced…

6 months ago

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage…

6 months ago